Search research articles
Contact Us
Filters
Showing results (31-40 of 61) with videos related to
Page
of 7
Sort By:
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
July 14, 2021
Evaluation of [<sup>18</sup>F]-JNJ-64326067-AAA tau PET tracer in humans
Suzanne L Baker, Karine Provost, Wesley Thomas, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 28, 2019
[<sup>11</sup>C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson's disease and healthy volunteers
Donatienne Van Weehaeghe, Michel Koole, Mark E Schmidt, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 22, 2024
Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study
Mark E Schmidt, Iva Kezic, Vanina Popova, et al.
Biological Psychiatry Global Open Science
|
May 25, 2026
Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study
James A Palmer, Matthew Klein, Dai Wang, et al.
Biological Psychiatry
|
January 7, 2003
Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment
Michael E Henry, Marc J Kaufman, John Hennen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 15, 2020
Clinical evaluation of [<sup>18</sup>F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease
Mark E Schmidt, Luc Janssens, Diederik Moechars, et al.
Neuroimage
|
February 5, 2021
Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [<sup>11</sup>C]-ABP688 PET imaging in healthy volunteers
Johannes Streffer, Valerie Treyer, Alfred Buck, et al.
Neurology
|
February 13, 2018
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Enchi Liu, Dai Wang, Reisa Sperling, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 22, 2025
Dosimetry and kinetic modelling of [<sup>18</sup>F]JNJ-64511070, a novel PET ligand to quantify AMPA-associated TARP-γ8 receptors in the human brain
Michel Koole, Mark E Schmidt, Anja Hijzen, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
June 25, 2025
EC<sub>50</sub> images reveal reproducible spatial variation in drug affinity across single- and repeat-dose occupancy studies
Alaaddin Ibrahimy, Su Jin Kim, Mark E Schmidt, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 61) with videos related to
Sort By:
Page
of 7
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
July 14, 2021
Evaluation of [<sup>18</sup>F]-JNJ-64326067-AAA tau PET tracer in humans
Suzanne L Baker, Karine Provost, Wesley Thomas, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 28, 2019
[<sup>11</sup>C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson's disease and healthy volunteers
Donatienne Van Weehaeghe, Michel Koole, Mark E Schmidt, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
April 22, 2024
Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study
Mark E Schmidt, Iva Kezic, Vanina Popova, et al.
Biological Psychiatry Global Open Science
|
May 25, 2026
Efficacy and Safety of the Selective, Brain-Penetrant P2X7 Receptor Antagonist JNJ-55308942 (Zanvipixant) in Bipolar Depression: A Phase 2a Study
James A Palmer, Matthew Klein, Dai Wang, et al.
Biological Psychiatry
|
January 7, 2003
Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment
Michael E Henry, Marc J Kaufman, John Hennen, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 15, 2020
Clinical evaluation of [<sup>18</sup>F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease
Mark E Schmidt, Luc Janssens, Diederik Moechars, et al.
Neuroimage
|
February 5, 2021
Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [<sup>11</sup>C]-ABP688 PET imaging in healthy volunteers
Johannes Streffer, Valerie Treyer, Alfred Buck, et al.
Neurology
|
February 13, 2018
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Enchi Liu, Dai Wang, Reisa Sperling, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
July 22, 2025
Dosimetry and kinetic modelling of [<sup>18</sup>F]JNJ-64511070, a novel PET ligand to quantify AMPA-associated TARP-γ8 receptors in the human brain
Michel Koole, Mark E Schmidt, Anja Hijzen, et al.
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism
|
June 25, 2025
EC<sub>50</sub> images reveal reproducible spatial variation in drug affinity across single- and repeat-dose occupancy studies
Alaaddin Ibrahimy, Su Jin Kim, Mark E Schmidt, et al.
Page
of 7